SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
Median Overall Survival (mOS) of 8.9 Months in Patients with AML MR and 8.8 mOS in Relapsed or Refractory to Venetoclax-Based Regimens at 30 mg BIW Dose Level Surpasses the Historical Benchmark of 2.4 Months
FDA Recommends Advancement towards a Trial Including Newly Diagnosed First-Line AML Patient Cohorts That May Support a New Drug Application; Trial Preparation Underway with Enrollment Expected to Begin by Q1 2026
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ('SELLAS' or the 'Company'), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that is has met all primary endpoints in its Phase 2 trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML).
The Phase 2 clinical trial of SLS009 is an open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels, 45 mg and 60 mg. In the 60 mg dose cohort, patients were treated with either a 60 mg dose once per week or a 30 mg dose two times per week. The trial was expanded to include ASXL1-mutated AML patients as well as patients with myelodysplasia-related cytogenetic abnormalities other than ASXL1 mutations. The target response rate for this Phase 2 trial, at the optimal dose level, was at least 20% and a target median survival of at least 3 months. The primary endpoint for the trial was overall response rate (ORR), and key secondary endpoints included overall survival (OS), safety, and tolerability.
The trial met all endpoints, demonstrating strong efficacy and favorable safety and tolerability with robust anti-tumor activity. Based on these data, the Company plans to advance SLS009 into a randomized trial that will expand into the newly diagnosed AML populations where earlier intervention may enhance therapeutic outcomes, as well as patients refractory to venetoclax and azacitidine, with the study to support a potential New Drug Application (NDA) with the FDA.
'We are excited to report that our Phase 2 trial met all key endpoints, with clinical responses and survival outcomes that exceed targeted expectations and historical benchmarks,' said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. 'AML remains an area of urgent unmet medical need, particularly for patients with relapsed or refractory disease, where standard treatments are often ineffective and poorly tolerated. What sets SLS009 apart is its consistent efficacy across a broad range of molecular subtypes. The remarkable response rates of 44% among AML MR patients, 50% among ASXL1-mutated AML MR, and 50% among M4/M5 patients at the optimal 30 mg BIW dose far exceed the targeted 20% benchmark. We saw a clear survival benefit with median OS reaching 8.8 months in patients refractory to venetoclax-based regimens in the cohort of patients with median 1 prior line of therapy, surpassing the historical median of 2.4 months and 4.1 months in cohorts with median 2 lines of prior therapy, versus 1.8 months reported in similar patient population. The treatment was also well-tolerated, with no dose-limiting toxicities across any treatment arm, validating both the biological selectivity and safety profile of our approach. We believe these data strongly support the potential of SLS009 to meaningfully extend life in patients with otherwise limited options, and we look forward to sharing these findings in more detail in the future. With the expected Phase 3 REGAL study final analysis by year-end, our galinpepimut-S (GPS) immunotherapy and SLS009 are complementary therapies that together enable us to hopefully address AML patients across the treatment spectrum — from early intervention to maintenance.'
Key Phase 2 Results:
Patients Characteristics:
54 evaluable r/r AML patients who previously failed venetoclax-based therapies were enrolled and treated with SLS009, and venetoclax/azacitidine; patients were enrolled across all five cohorts. Among the 54 treated patients, 47 had AML MR (87%) and 23 had ASXL1 mutations (43%).
47 out of 54 had AML MR (acute myeloid leukemia with myelodysplasia-related changes).
Among AML MR patients,17 had myelomonocytic/myelomonoblastic subtype of AML (M4 and M5), representing 31% of all patients.
All patients had adverse risk cytogenetics except one patient who had intermediate risk cytogenetics.
The median age of all patients was 69.
Median number of prior lines of therapy was 2.
Efficacy:
The results exceeded the pre-specified ORR threshold of 20%, demonstrating robust clinical activity and supporting advancement into late-stage development.
The ORR in all evaluable patients was 33% across all cohorts and dose levels and 40% for the 30mg BIW dose level.
At the 30 mg BIW dose, among AML MR patients, the ORR was 44%.
The highest efficacy was observed among patients with ASXL1 mutations, with an ORR of 50% (9/18) at 30 mg BIW dose levels and M4/M5 patients with 50% (6/12) ORR.
The mOS surpassed the historical benchmark of best available therapy of 2.4 months1 for patients who received one prior line of therapy and 1.8 months for those who received more than one prior line of therapy.
The mOS for patients treated with 30mg BIW, with a median of 1 prior line of therapy, was 8.8 months, while the mOS in AML MR patients reached 8.9 months vs. 2.4 months with best available therapy.
The mOS for cohorts with a median of 2 prior lines of therapies was 4.1 months vs.1.8 months with best available therapy.
Safety:
The addition of SLS009 to the venetoclax/azacitidine regimen was well tolerated and did not result in increased toxicities compared to ven/aza alone. No dose-limiting toxicities were observed across all dose levels.
Front Line Trial Planning Underway Following FDA Guidance
Following a productive end of Phase 2 meeting, the FDA recommended that SELLAS proceeds into a trial to include newly diagnosed, first-line AML patients eligible for venetoclax/azacitidine (aza/ven) therapy, where the agency believes clinical benefit might be greatest.
The randomized 80-patient trial is currently in preparation and is expected to begin enrollment by Q1 2026. The trial will include two groups:
Predictive biomarker cohort: Newly diagnosed patients unlikely to benefit from standard aza/ven therapy based on molecular profiling
Early resistance cohort: Patients who initiate treatment with aza/ven but demonstrate confirmed lack of any response after two treatment cycles
This precision approach allows SELLAS to target subpopulations with high unmet need and greatest potential for benefit.
'These SLS009 results represent an important advancement for patients with r/r AML, where treatment options remain limited and outcomes are often poor,' said Dr. Yair Levy, Director of Hematologic Malignancies Research at Texas Oncology Baylor University Medical Center. 'The response rates and survival outcomes are particularly compelling, especially given the consistency of responses across high-risk molecular subtypes and the favorable safety profile. What's especially encouraging is the opportunity to now explore this therapy in the first-line setting, where outcomes are often dictated by how patients respond to initial treatment. The FDA's recognition of this unmet need and its support for a trial in newly diagnosed patients reflects SLS009's potential to address a critical gap in AML care.'
'Following constructive FDA guidance, we are preparing the trial focused on newly diagnosed AML patients as well as those early refractory to venetoclax and azacitidine,' said Dragan Cicic, MD, Chief Development Officer of SELLAS. 'The study will include two groups – one comprising patients predicted not to benefit from standard aza/ven, based on cytogenetic risk factors, and a second comprising patients who begin aza/ven treatment but demonstrate confirmed resistance after two cycles. We believe earlier intervention with SLS009 may offer greater clinical benefit before patients' bone marrow reserve is depleted by disease or prior therapies, and before the disease evolves into more resistant and aggressive forms. Data from other recent clinical trials suggests meaningful differences in response rates between newly diagnosed and relapsed/refractory patients, reinforcing the importance of this strategic approach. In addition, our ongoing collaboration with one of the nation's most prestigious cancer centers continues to generate insights in genomics, proteomics, and transcriptomics, which will refine patient selection and our precision medicine strategy and help us unlock the full potential of SLS009 as we prepare to enter pivotal development.'
Zainaldin et al, Leukemia and Lymphoma, 2022
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as 'plan,' 'expect,' 'anticipate,' 'may,' 'might,' 'will,' 'should,' 'project,' 'believe,' 'estimate,' 'predict,' 'potential,' 'intend,' or 'continue' and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption 'Risk Factors' in SELLAS' Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
a few seconds ago
- Washington Post
A dazzling speculative novel ponders life's possibilities
The Oscar-nominated film 'Past Lives' was the wistful story of a love triangle. But the tension for its female protagonist was not simply between two partners but between two selves — a past in Seoul lived in Korean and a present as a New Yorker thriving in English. Suspended in that tension between here and there, its screenplay by director Celine Song was a classic work of immigrant fiction. Counterfactuals and imagined homelands have always haunted and inspired displaced artists. In his debut novel, 'Archive of Unknown Universes,' the brilliant young writer Ruben Reyes Jr. turns that art of speculation into a riveting saga of answers.
Yahoo
28 minutes ago
- Yahoo
Institutional investors have a lot riding on Vertiv Holdings Co (NYSE:VRT) with 82% ownership
Key Insights Institutions' substantial holdings in Vertiv Holdings Co implies that they have significant influence over the company's share price A total of 25 investors have a majority stake in the company with 46% ownership Insiders have been selling lately This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Every investor in Vertiv Holdings Co (NYSE:VRT) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 82% to be precise, is institutions. In other words, the group stands to gain the most (or lose the most) from their investment into the company. And as as result, institutional investors reaped the most rewards after the company's stock price gained 4.7% last week. One-year return to shareholders is currently 51% and last week's gain was the icing on the cake. Let's delve deeper into each type of owner of Vertiv Holdings Co, beginning with the chart below. View our latest analysis for Vertiv Holdings Co What Does The Institutional Ownership Tell Us About Vertiv Holdings Co? Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. We can see that Vertiv Holdings Co does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Vertiv Holdings Co's historic earnings and revenue below, but keep in mind there's always more to the story. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. We note that hedge funds don't have a meaningful investment in Vertiv Holdings Co. The Vanguard Group, Inc. is currently the company's largest shareholder with 9.9% of shares outstanding. In comparison, the second and third largest shareholders hold about 8.9% and 2.1% of the stock. A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Vertiv Holdings Co While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data suggests that insiders own under 1% of Vertiv Holdings Co in their own names. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Though their holding amounts to less than 1%, we can see that board members collectively own US$162m worth of shares (at current prices). In this sort of situation, it can be more interesting to see if those insiders have been buying or selling. General Public Ownership The general public-- including retail investors -- own 16% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Vertiv Holdings Co better, we need to consider many other factors. Be aware that Vertiv Holdings Co is showing 2 warning signs in our investment analysis , you should know about... Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Here's How Much You Must Make To Afford a Home in the West's Most Livable Cities
If you're thinking of heading west and looking for affordable, livable locales, Oregon may be worth a look. Also See: Learn More: The Beaver State boasts six of the 10 best blends of livability and affordability in the Western U.S., based on a recent GOBankingRates analysis of data from AreaVibes, Sperling's BestPlaces and other sources. Before you pack your bags, though, it's worth learning how much you would need to make to afford a home. Here's GBR's full list, along with the minimum salary required for homeownership, median household income and some additional information about each location. Kaysville, Utah Livability score: 89 Salary needed (annual cost of living): $69,593 Median household income: $128,996 You'll find Kaysville in northern Utah, about 20 miles north of Salt Lake City. A single-family home in Kaysville is worth about $650,000. Living costs will run you about $5,800 a month. Check Out: Find Out: Orem, Utah Livability score: 89 Salary needed (annual cost of living): $59,815 Median household income: $81,292 Orem is located just north of Provo and about 40 miles south of Salt Lake City. Only about 10 percent of Orem's 97,000+ residents are age 65 or older. You'll spend just shy of $5,000 a month on average for living costs here. Discover More: Raleigh Hills, Oregon Livability score: 89 Salary needed (annual cost of living): $92,776 Median household income: $109,306 Raleigh Hills is a suburb of Portland with about 7,000 residents. Single-family homes aren't cheap here, with average values approaching $1 million. An average monthly mortgage here will run you about $5,700. Beaverton, Oregon Livability score: 89 Salary needed (annual cost of living): $65,363 Median household income: $94,279 Beaverton is located about 10 miles west of Portland and has about 100,000 residents. Beaverton's average monthly cost of living (around $5,400) places it in the middle of the pack among AreaVibes' most livable cities. Single-family homes in Beaverton are worth $565,000 on average. Gladstone, Oregon Livability score: 89 Salary needed (annual cost of living): $62,124 Median household income: $90,395 Another Portland suburb, Gladstone is located about 12 miles to the south. About a fifth of Gladstone's 12,000 residents are 65 and older. Gladstone is somewhat less expensive than some other Portland suburbs, with average single-family homes valued at $514,000 and average monthly living costs coming in around $5,200. Central Point, Oregon Livability score: 90 Salary needed (annual cost of living): $52,234 Median household income: $80,450 Central Point is located in southern Oregon, a few miles northwest of Medford. With average monthly living costs around $4,300, Central Point is significantly less expensive than many options in the Portland area. See More: Lafayette, Colorado Livability score: 90 Salary needed (annual cost of living): $75,764 Median household income: $110,431 Lafayette sits about 25 miles north of Denver. Single-family homes in Lafayette are worth $731,000 on average, with monthly mortgages around $4,300. Battle Ground, Washington Livability score: 90 Salary needed (annual cost of living): $68,256 Median household income: $100,185 Battle Ground is located near the Washington-Oregon border, about 25 miles north of Portland. Average monthly mortgages in Battle Ground are less than $3,600, and average monthly living costs are about $5,700. On average, single-family homes here are worth just over $600,000. Milwaukie, Oregon Livability score: 91 Salary needed (annual cost of living): $61,690 Median household income: $82,422 Milwaukie is a suburb of Portland with about 22,000 residents and average monthly mortgages of around $3,000. Single-family homes in Milwaukie are worst just over $500,000. Sherwood, Oregon Livability score: 92 Salary needed (annual cost of living): $72,351 Median household income: $110,616 You'll find Sherwood about 20 miles southwest of Portland. Sherwood is a somewhat young city, with less than 11% of its 21,000 residents aged 65 or older. Homes here are worth around $660,000 on average. Monthly living costs will run you about $6,000. Editor's note: Photos are for representational purposes only and might not reflect the exact locations listed. Methodology: For this study, GOBankingRates analyzed cities across the United States with the highest livability scores, as sourced from AreaVibes. The 30 most livable cities in each state were identified. To qualify for this study, each city had to have all data points available and a total population of at least 5,000. All relevant data was sourced from the U.S. Census American Community Survey, Sperling's BestPlaces, the Bureau of Labor Statistics Consumer Expenditure Survey, Zillow Home Value Index and Federal Reserve Economic Data. All data was collected on and is up to date as of May 14, 2025. More From GOBankingRates 10 Unreliable SUVs To Stay Away From Buying This article originally appeared on Here's How Much You Must Make To Afford a Home in the West's Most Livable Cities Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
